A 13-Week Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose-Response Trial Assessing the Safety, Tolerability and Efficacy of AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus.
Phase of Trial: Phase II
Latest Information Update: 27 Jan 2014
At a glance
- Drugs Lixisenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Sanofi
- 07 Jun 2017 Biomarkers information updated
- 01 Sep 2010 Results published in Diabetic Medicine.
- 01 Oct 2009 Results of a pharmcodynamic substudy presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History